Literature DB >> 12441035

The pharmacology and clinical relevance of proton pump inhibitors.

Philip O Katz1, Christine Frissora.   

Abstract

Gastroesophageal reflux disease is a complex, multifaceted disorder affecting a large proportion of the US population. Its management is based on the principle of optimal antisecretory therapy, mainly with proton pump inhibitors (PPIs). The optimal treatment outcome is complete symptom relief, which can be achieved with optimal use of PPIs. PPI treatment requires an understanding of the pharmacology of these agents as well as their clinical efficacy, strengths, and weaknesses. This paper reviews the pharmacology of PPIs, the principles of optimal dosing, nocturnal gastric acid breakthrough and its clinical importance, and a treatment approach to gastroesophageal reflux disease using these agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441035     DOI: 10.1007/s11894-002-0021-3

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  15 in total

1.  Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.

Authors:  J G Hatlebakk; P O Katz; L Camacho-Lobato; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

2.  Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

Authors:  M Besancon; A Simon; G Sachs; J M Shin
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

3.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

4.  Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls.

Authors:  B Kuo; D O Castell
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

5.  Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).

Authors:  V Stanghellini
Journal:  Scand J Gastroenterol Suppl       Date:  1999

6.  Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.

Authors:  P O Katz; J G Hatlebakk; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

7.  Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.

Authors:  L P Leite; B T Johnston; R J Just; D O Castell
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

Review 8.  Extraesophageal gastroesophageal reflux disease. Presentations and approach to treatment.

Authors:  M B Fennerty
Journal:  Gastroenterol Clin North Am       Date:  1999-12       Impact factor: 3.806

9.  Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.

Authors:  P L Peghini; P O Katz; N A Bracy; D O Castell
Journal:  Am J Gastroenterol       Date:  1998-05       Impact factor: 10.864

10.  Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.

Authors:  P O Katz; C Anderson; R Khoury; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  1998-12       Impact factor: 8.171

View more
  3 in total

Review 1.  Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

2.  Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.

Authors:  Jin-Yan Luo; Chun-Yan Niu; Xue-Qin Wang; You-Ling Zhu; Jun Gong
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

3.  Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.

Authors:  José María Remes-Troche; Sergio Sobrino-Cossío; Julio César Soto-Pérez; Oscar Teramoto-Matsubara; Miguel Morales-Arámbula; Antonio Orozco-Gamiz; José Luis Tamayo de la Cuesta; Gualberto Mateos
Journal:  Clin Drug Investig       Date:  2014-02       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.